威高骨科(688161) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥287,805,032.83, a decrease of 39.44% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2022 was ¥44,329,095.50, down 64.59% year-on-year[7]. - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥41,592,203.43, a decline of 65.40% compared to the previous year[11]. - The basic earnings per share for Q3 2022 was ¥0.11, a decrease of 64.52% year-on-year[11]. - The company's total revenue for the first three quarters of 2022 was RMB 1,393,031,318.98, a decrease of approximately 11.3% compared to RMB 1,570,592,770.80 in the same period of 2021[31]. - Total operating revenue for the first three quarters of 2022 was CNY 1,555,852,228.04, a decrease from CNY 1,714,941,327.13 in the same period of 2021, representing a decline of approximately 9.3%[42]. - Net profit for the third quarter of 2022 was CNY 441,974,346.24, down from CNY 495,867,418.87 in the same quarter of 2021, reflecting a decrease of about 10.9%[38]. - The total profit for the third quarter of 2022 was CNY 511,330,868.13, down from CNY 587,118,379.80 in the same quarter of 2021, a decrease of about 12.9%[38]. - The total comprehensive income for the third quarter of 2022 was CNY 441,974,346.24, compared to CNY 495,867,418.87 in the same quarter of 2021, reflecting a decrease of about 10.9%[40]. Expenses and Costs - Research and development expenses totaled ¥27,373,135.34 in Q3 2022, representing 9.51% of operating revenue, an increase of 3.05 percentage points from the previous year[11]. - Total operating costs for the third quarter of 2022 were CNY 906,008,818.56, down from CNY 983,109,988.75 in the previous year, a reduction of about 7.8%[38]. - Research and development expenses for the third quarter of 2022 were CNY 83,299,404.36, slightly up from CNY 81,678,494.11 in the same quarter of 2021, an increase of approximately 2.0%[38]. - The company reported a financial expense of CNY -30,263,287.56 in the third quarter of 2022, compared to CNY -21,502,639.59 in the same quarter of 2021, indicating a worsening of financial costs[38]. - Tax expenses for the third quarter of 2022 were CNY 69,356,521.89, down from CNY 91,250,960.93 in the same quarter of 2021, a decrease of approximately 24.0%[38]. Assets and Liabilities - Total assets at the end of Q3 2022 were ¥5,618,569,023.82, an increase of 3.98% compared to the end of the previous year[11]. - The company's total equity attributable to shareholders increased by 5.23% year-on-year, reaching ¥4,768,548,730.81[11]. - The total liabilities of the company as of September 30, 2022, were RMB 849,859,015.88, a slight decrease from RMB 865,641,860.04 at the end of 2021[30]. - The company's inventory as of September 30, 2022, was RMB 652,425,162.50, up from RMB 564,900,238.24 at the end of 2021, indicating an increase of approximately 15.5%[26]. - The total equity attributable to shareholders as of September 30, 2022, was RMB 4,768,548,730.81, an increase from RMB 4,531,539,606.55 at the end of 2021, reflecting a growth of approximately 5.2%[30]. Cash Flow - The company's cash flow from operating activities for the year-to-date period decreased by 43.08% due to reduced sales receipts[11]. - The net cash flow from operating activities was 297,196,299.48, a decrease of 43% compared to 522,133,081.74 from the previous period[45]. - The total cash outflow from operating activities amounted to 1,258,655,928.56, up from 1,192,808,245.39, indicating a 5.5% increase[45]. - The net cash flow from investing activities was 12,592,467.71, recovering from a negative cash flow of -90,847,230.13 in the previous period[45]. - The net cash flow from financing activities was -223,611,921.07, a sharp decline from 1,374,176,588.27 in the previous period[47]. - The ending balance of cash and cash equivalents was 2,641,597,405.24, down from 3,406,327,136.38 in the previous period[47]. - The company paid 211,442,497.13 in dividends and interest, compared to no payments in the previous period[45]. - The cash outflow for investment activities was 493,425,540.15, a significant increase from 92,088,678.57 in the previous period[45]. - The company received 13,886,140.13 from financing activities, a decrease from 1,404,644,965.51 in the previous period[45]. - The cash flow from other investment activities increased to 3,679,117.10 from 1,160,227.20 in the previous period[45]. Market Position and Strategy - The decline in operating revenue was attributed to cautious purchasing behavior from downstream terminals and distributors amid ongoing national volume-based procurement for spinal products[14]. - The company successfully won all bids in the national centralized procurement of orthopedic spinal consumables announced on September 30, 2022, which is expected to enhance market share[22]. - The company plans to continue focusing on innovation and product development in the orthopedic medical device sector to strengthen its market position[22]. - The company maintains a multi-brand strategy to enhance its market share across various segments in the orthopedic field[22]. - The company's net profit for the first three quarters of 2022 is not explicitly stated, but the decrease in total revenue suggests potential challenges in profitability[31].